Therapeutic agents useful for treating pain

Details Therapeutic agents useful for treating pain Therapeutic agents useful for treating pain

2007-10-09

2007-10-09

Habte, Kahsay (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S146000

Reexamination Certificate

active

10607563

ABSTRACT:
A compound of formula:wherein A, Ar, R3, R6, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Cyanoiminopiperazine Compound”), compositions comprising an effective amount of a Cyanoiminopiperazine Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cyanoiminopiperazine Compound are disclosed.

REFERENCES:
patent: 4439606 (1984-03-01), Du et al.
patent: 4450272 (1984-05-01), Du et al.
patent: 5039680 (1991-08-01), Imperato et al.
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5198459 (1993-03-01), Imperato et al.
patent: 5232934 (1993-08-01), Downs
patent: 5430033 (1995-07-01), Cliffe et al.
patent: 5442064 (1995-08-01), Pieper et al.
patent: 5461047 (1995-10-01), Hansen, Jr. et al.
patent: 5556837 (1996-09-01), Nestler et al.
patent: 5556838 (1996-09-01), Mayer et al.
patent: 5574052 (1996-11-01), Rose et al.
patent: 5756504 (1998-05-01), Bock et al.
patent: 5762925 (1998-06-01), Sagen
patent: 5789412 (1998-08-01), Halazy et al.
patent: 5792768 (1998-08-01), Kulagowski et al.
patent: 5792769 (1998-08-01), Lu et al.
patent: 6020349 (2000-02-01), Ankersen et al.
patent: 6028195 (2000-02-01), Cho et al.
patent: 6083960 (2000-07-01), Ankersen et al.
patent: 6109269 (2000-08-01), Rise et al.
patent: 6204284 (2001-03-01), Beer et al.
patent: 6329395 (2001-12-01), Dugar et al.
patent: 6423716 (2002-07-01), Matsuno et al.
patent: 2002/0019389 (2002-02-01), Kim et al.
patent: 2003/0153596 (2003-08-01), Suh et al.
patent: 2003/0158188 (2003-08-01), Lee et al.
patent: 2003/0158198 (2003-08-01), Lee et al.
patent: 2003/0212140 (2003-11-01), Suh et al.
patent: 2004/0019099 (2004-01-01), Aslanian et al.
patent: 2004/0048843 (2004-03-01), Ting et al.
patent: 2004/0097483 (2004-05-01), Zeng et al.
patent: 2004/0204397 (2004-10-01), Chaturvedula et al.
patent: 2006/0004053 (2006-01-01), Arnould
patent: 1 122 242 (2001-08-01), None
patent: 7 804 136 (1979-04-01), None
patent: WO96/21648 (1996-07-01), None
patent: WO98/00402 (1998-01-01), None
patent: WO99/07672 (1999-01-01), None
patent: WO 00/52001 (2000-09-01), None
patent: WO 02/05819 (2002-01-01), None
patent: WO 02/18335 (2002-03-01), None
patent: WO 03/022809 (2003-03-01), None
patent: WO 03/062209 (2003-07-01), None
patent: WO 03/068749 (2003-08-01), None
patent: WO 2004/002983 (2004-01-01), None
patent: WO 2004/064721 (2004-08-01), None
Berkow et al., “The Merck Manual of Medical Information,” pp. 345-350, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 352-355, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 496-500, 1997.
Berkow et all., “The Merck Manual of Medical Information,” pp. 525-526, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 528-530, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 530-532, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 631-634, 1997.
Chiamulera et al., “Reinforcing and Locomotor Stimulant Effects of Cocaine are Absent in mGluR5 Null Mutant Rice,” Nature Neurosci., 4(9):873-874, 2001.
Cooke, “Glycopyrroate in Bladder Dysfunction,” SA Medical J., 63:3, 1983.
Di Marzo et al., “Endovanilloid Signaling in Pain,” Current Opinion in Neurobiology, 12:372-379, 2002.
Dogrul et al., “Peripheral and Spinal Antihyperalgesic Activity of SIB-1757, A Metabotropic Glutamate Receptor (mGluR5) Antagonist, in Experimental Neuropathic Pain in Rats,” Neurosci. Lett., 292(2):115-118, 2000.
Foley, “Pain” Cecil Textbook of Medicine, pp. 100-107, 1996.
Fundytus et al, “Antisense Oligonucleotide Knockdown of mGluR1Alleviates Hyperalgesia and Allodynia Associated with Chronic Inflammation,” Pharmacol., Biochem. & Behavior, 73:401-410, 2002.
Fundytus et al., “In vivo Antinociceptive Activity of Anti-Rat mGluR1and mGluR5Antibodies in Rats,” NeuroReport, 9:731-735, 1998.
Fundytus et al., “Knockdown of Spinal Metabotropic Glutamate Receptor 1 (mGluR1) Alleviates Pain and Restores Opioid Efficacy after Nerve Injury in Rats,” British J. Pharmacol., 132:354-367, 2001.
Fundytus, “Glutamate Receptors and Nociception Implications for the Drug-Treatment of Pain,” CNS Drugs, 15:29-58, 2001.
Goodman and Gillman's the Pharmaceutical Basis of Therapeutics 506, 901-915 (J. Hardman and L. Limbird Eds., 9thed. 1996).
Herzog et al., “Urinary Incontinence: Medical and Psychosocial Aspectis,” Annu. Rev. Gerontol. Geriatr., 9:74-119, 1989.
Kwak et al., “A Capsaicin-Receptor Antagoinist, Capsazepine Reduces Inflammation-Induced Hyperalgesic Responses in the Rat: Evidence for an Endogenous Capsaicin-Like Substance,” Neurosci., 84:619-626, 1998.
Levin et al., “Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder,” J. Urology, 128:396-398, 1982.
Matsuno et al., “Potent and Selective Inhibitors of PGDF Receptor Phosphorylation,” J. Medicinal Chem., 45:4513-23, 2002.
Meyer et al., 5-(1-Piperazinyl)-1H-1,2,4-triazol-3-amines as Antihypertiensive Agents, J. Medicinal Chem., 32:593-7, 1989.
Mirakhur et al., “Glycopyrrolate: Pharmacology and Clinical Use,” Anesthesia, 38:1195-1204, 1983.
Ohkubo et al., “The Selective Capsaicin Antagonist Capsazepine Abolishes the Antinociceptive Action of Eugenol and Guaiacol,” J. Dent. Res., 76(4): Apr. 1997.
Ossowska et al., “Blockade of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Produces Antiparkinsonian-Like Effects in Rats,” Neuropharmacol., 41:413-420, 2001.
Pan et al., “Soluble Polymer-Supported Synthesis of Arylpiperazines,” Tett. Lett., 39:9505-9508 1998.
Reid et al., “Synthese and Reaktionem Neuer Thiazol-Und Triazol-Abkömmlinge,” Chemische Berichte, 116:(4) 1548, 1983.
Resnick, “Urinary Incontinence,” Lancet, 346:94-99, 1995.
Tatarczynska et al., Potential Anxiolytic- and Antidepressant-Like Effects of MPEP, A Potent, Selective and Systemically Active mGlu5 Receptor Antagonist, British J. Pharmacol., 132(7):1423-1430, 2001.
Urban et al., “In Vivo Pharmacology of SDZ 249-665, A Novel, Non-Pungent Capsaicin Analogue,” Pain, 89:65-74 2000.
Walker et al., “Metabotropic Glutamate Receptor Subtype 5 (mGlu5) and Nociceptive Function. I. Selective Blockade of mGlu5 Receptors in Models of Acute, Persistent and Chronic Pain,” Neuropharmacol., 40:1-9, 2000.
Wein, “Pharmacology of Incontinence,” Urologic Clinics of North America, 22(3):557-577, 1995.
Spooren et al., “Novel Allosteric Antagonists Shed Light on mGlu5Receptors and CNS Disorders,” Trends Pharmacol. Sci., 22(7):331-337, 2001.
Wu et al., “Multiple Sensory and Functional Effects of Non-Phenolic Aminodimethylene Nonivamide: An Approach To Capsaicin Antagonist,” Gen. Pharmac., 27(1):151-158 1996.
Wrigglesworth et al., “Capsaicin-like Agonists,”Drugs of the Futrue 23(5):531-538 (1998).
Szallasi et al., “Vanilliid (Capsaicin) Receptors and Mechanisma,”Pharmacol. Revs. 51(2):159-211 (1999).
Szallasi et al., “The Cloned Rat Vanilloid Receptor VR1 Mediates Both R-Type Binding and C-Type Calcium Response in Dorsal Root Ganglion Neurons,”Molec. Pharmacol. 56:581-587 (1999).
Bevan et al., “Vanilloid Receptors: Pivotal Molecules in Nocciception,”

Affiliated with

Also associated with

Rating

Therapeutic agents useful for treating pain does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic agents useful for treating pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents useful for treating pain will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3895736